vTv Therapeutics Announces Issuance of US Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

vTv Therapeutics, Inc. announced that the US Patent and Trademark Office recently issued a patent to Cantex Pharmaceuticals, Inc. that covers claims related to the use of azeliragon as a potential treatment of glioblastoma multiforme.